Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Minocycline (Primary) ; Doxycycline hyclate
  • Indications Rosacea
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MVOR-2
  • Sponsors Dr Reddys Laboratories; Journey Medical Corporation

    • Most Recent Events

    • 18 Mar 2024 According to a Journey Medical Corporation media release, FDA has accepted the Company's New Drug Application ("NDA") for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act ("PDUFA") goal date of November 4, 2024
    • 05 Jan 2024 According to a Journey Medical Corporation media release, based on positive data from Journey Medical's two DFD-29 Phase 3 clinical trials, the Company has submitted a New Drug Application (NDA) to the FDA seeking approval for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults.
    • 02 Jan 2024 According to a Journey Medical Corporation media release,company a has entered into a credit facility with an affiliate of SWK Holdings Corporation a specialized finance company with a focus on the global healthcare sector, providing for borrowings of up to $20 million and this The funding will support general corporate purposes, as well as anticipated expenses for DFD-29, including an upcoming New Drug Application submission pending FDA approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top